The global superdisintegrants market size was valued at around USD 258.6 million in 2016 and is expected to grow at a CAGR of 7.2% over the forecast period. Factors such as growing generic drugs market, geriatric and pediatric population who have difficulty in swallowing tablet/capsules and development of new superdisintegrants for the pharmaceutical industry is driving the growth of the market.
Furthermore, increasing pharmaceutical consumption by the global population is in turn increasing the demand for various superdisintegrants. Pharmaceuticals now account for about 20% of total health spending in Organization for Economic Co-operation and Development (OECD) countries; out of which Canada has emerged out to be among the top pharmaceutical spender on the OECD list.
U.S. superdisintegrants market revenue, by product, 2014 - 2025 (USD Million)
Crospovidone dominated the product segment in 2016. Crospovidone has the ability to stabilize the amorphous state of drugs due to inhibition of drug recrystallization and a rapid solidification rate. In addition, crospovidone has excellent disintegration and dissolution enhancing effect, which is usually used in the preparation of tablets, granules, and capsules. All these factors would together propel the growth of the crospovidone segment during the forecast period.
However, the others segment which includes natural superdisintegrants such as Isapghula husk, gellan gum, and locust bean gum is expected to grow at the highest CAGR during the forecast period. It has instant swelling features when it comes into contact with water due to its high hydrophilic nature, which results in the rapid disintegration of tablets. Apart from these superdisintegrants, researchers are continuously investigating novel disintegrating agents. It includes testing of modified natural products, such as chitin, chitosan, polymerized agar acrylamide, xylem, cross-linked carboxymethyl guar, and modified tapioca starch.
Tablets and capsules segment dominated the market in 2016. Tablets have a longer shelf life, accurate dosing, and are cost-effective. Disintegrants are one of the most significant excipients of tablet and capsule formulation and are added to induce breakup when it encounters aqueous fluid. Tablets and capsules have quick-dissolving dosage form recognized by the FDA and are listed in the approved drug products with therapeutic equivalence evaluations, which would boost the growth of the segment. The number of disintegrants used for multifunctional tablet and capsule formulation includes starch (and its derivatives), crospovidone, cellulose, and others.
The Mouth-dissolving film segment is expected to witness the highest growth during the forecast period. Advantages and unique properties, availability of larger surface area for rapid disintegrating and dissolution in the oral cavity, accurate dosing, rapid onset of action, and improved patient compliance for the pediatric population are a few factors contributing towards the growth of the segment.
Global superdisintegrants market revenue, by product, 2016 (%)
North America dominated the superdisintegrants industry with the largest revenue share in 2016. Increasing demand for generic drugs, better innovation in the manufacture of superdisintegrants, and the techniques used to manufacture them are a few high impact rendering drivers for the market. In addition, North America is home to some of the most significant players who are operating in the field of superdisintegrants market.
On the other hand, Asia Pacific is expected to show the fastest growth during the forecast period. Factors such as increasing outsourcing of excipients including superdisintegrants, manufacturing of new superdisintegrants, and adoption of novel technologies (novel drug delivery system) are expected to drive growth in the Asia Pacific region.
Currently, the global superdisintegrants market is fragmented in nature with a number of players. Some of the top companies operating in this industry are Ashland Global Holdings Inc., Roquette Frères S.A., FMC Corporation, DFE Pharma, Huber Corporation, Nippon Soda Co., Ltd. The Dow Chemical Company and BASF SE. Mergers, acquisitions, and regional expansion are the key strategic undertakings of these companies to increase the market share during the forecast period.
Report Attribute |
Details |
Market size value in 2020 |
USD 8.8 billion |
Revenue forecast in 2025 |
USD 487 million |
Growth Rate |
CAGR of 7.2% from 2017 to 2025 |
Base year for estimation |
2016 |
Historical data |
2014 - 2015 |
Forecast period |
2017 - 2025 |
Quantitative units |
Revenue in USD Million and CAGR from 2017 to 2025 |
Report coverage |
Revenue forecast; company share; competitive landscape; growth factors and trends |
Segments covered |
Product, dosage form, region |
Regional scope |
North America; Europe; Asia Pacific; Latin America; MEA |
Country scope |
U.S.; Canada; U.K.; Germany; Japan; China; Brazil; Mexico; South Africa |
Key companies profiled |
Ashland Global Holdings Inc.; Roquette Frères; DFE Pharma; BASF SE; DowDuPont Inc.; JRS Pharma; Merck KGaA; Corel Pharma Chem. |
Customization scope |
Free report customization (equivalent up to 8 analysts working days) with purchase. Addition or alteration to country; regional & segment scope. |
Pricing and purchase options |
Avail customized purchase options to meet your exact research needs. Explore purchase options |
This report forecasts revenue growth at global, regional & country levels as well as provides an analysis of the latest trends and opportunities in each of the sub-segments from 2014 to 2025. For the purpose of this study, Grand View Research has segmented the global superdisintegrants market on the basis of product, dosage form, and region:
Product Outlook (Revenue, USD Million, 2014 - 2025)
Croscarmellose sodium
Crospovidone
Sodium starch glycolate
Ion exchange resin
Others
Dosage Form Outlook (Revenue, USD Million, 2014 - 2025)
Tablets and Capsules
Mouth-dissolving Films
Regional Outlook (Revenue, USD Million, 2014 - 2025)
North America
The U.S.
Canada
Europe
The U.K.
Germany
Asia Pacific
Japan
China
Latin America
Brazil
Mexico
MEA
South Africa
b. The global superdisintegrants market size was estimated at USD 324.9 million in 2019 and is expected to reach 349.2 million in 2020.
b. The global superdisintegrants market is expected to grow at a compound annual growth rate of 7.2% from 2017 to 2025 to reach USD 487 million by 2025.
b. North America dominated the superdisintegrants market with a share of 29.3% in 2019. This is attributable to increasing demand for generic drugs, and presence of major players in the region.
b. Some key players operating in the superdisintegrants market include Ashland Global Holdings Inc., Roquette Frères, DFE Pharma, BASF SE, DowDuPont Inc., JRS Pharma, Merck KGaA, Corel Pharma Chem.
b. Key factors that are driving the market growth include growing generic drugs market, emergence of novel superdisintegrants, and booming pharmaceutical industry in emerging economies.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.
"The quality of research they have done for us has been excellent."
Multiple therapeutic regimens are being followed across the globe in attempts to come up with a reliable treatment for Covid-19. One line of treatment includes the use of hydroxychloroquine, while a second treatment line focuses to use antiviral drugs used in the disease management of HIV. Both these approaches have surged demand from advanced antivirals and antimalarial drugs. This impacts the drug manufacturers as an off label indication for these drug classes has to be worked upon. At the moment, the WHO has not prescribed any of these approaches, neither they have commented if one is better than the other. The report will account for Covid19 as a key market contributor.